Risk Factors for Congenital Heart Defects: A case study





Admission Note

 BG XXX is the 3584 gram product of a 37 WBD singleton gestation to a 22 year old G2P1A1 Caucasian female via Csection 2° to late fetal decels and FTP.

Infant characteristics

- Sex ratio
 - Males > females
 - International HLHS OR=1.7 (95% CI:1.55-1.85)
- Weight
 - BWI SGA OR= 4.4 (95% CI: 2.9-6.8)
 - NBDPS SGA OR= 2.0-3.0
- Maternal ethnicity
 - BWI, Atlanta no differences

Maternal History

- PMHX: No diabetes, HTN
- PSHx: 2001 MVA liver lac and small intestinal injury s/p SBR
- Meds: PNV began @ 1st prenatal visit
- PObHx: G1 SAB

Diabetes and HLHS

- Baltimore Washington Infant Study
 - Cases (4/377):Controls (23/3572) HLHS: OR = 1.7 (95% CI:0.6-4.8)

- National Birth Defects Prevention Study
 - Cases (3/192):Controls (21/4086)
 - HLHS: OR = 1.8 (95% CI: 0.4-7.8)

Diabetes and Other CHDs

- Hypertrophic cardiomyopathy
- Double outlet right ventricle
- Truncus arteriosus
- Transpositon of the great arteries
- · VSD

Mechanism

- Hyperglycemia Oxidative Stress
- Hyperinsulinemia
- Hypoglycemia Lactic Acidosis
- Modifiers of diabetic embryopathy
 - Antioxidants
 - Lipids
 - Arachidonic Acid
- Genetic Variants

Maternal Medications



FDA Pregnancy Categories

- A Controlled studies in pregnancy (<1%)
- B Animal studies show no risk or human data are reassuring
- C Human data lacking; animal studies positive or not done (66%)
- D Human data show risk; benefit may outweigh
- X Animal or human data positive; no benefit

Maternal Hypertension

- Angiotensin-converting-enzyme (ACE) inhibitors
 - Tennessee Medicaid
 - 29,507 infants 1985-2000
 - OR = 3.7 (95% CI: 1.9 7.3)
- 1995 2002 use of ACE inhibitors increased from 2.4% to 4.4%

ACE inhibitors pose risk of birth defects

Mothers who used ACE inhibitors, a blood pressure treatment, were more than twice as likely to have babies with birth defects.

Percentage of birth defects



Multivitamins and Heart Defects



Botto LD, Mulinaire J, Erickson JD. Do multivitamins or folic acid supplements reduce the risk for congenital heart defects? Evidence and Gaps. Am J Med Genet 2003; 121A:95-101

Folic Acid Pathway





Gaps identified by Botto AJMG 2003

- Do multivitamins reduce the risk?
- How much do they reduce the risk?
- What is the magnitude of effect?
- What components of multivitamins account for effect?
- What components of multivitamins account for effect?
- What dose is most effective?
- What is the mechanism?
- Do gene-environment interactions play a role?

Admission Note

- SocHx: Denies smoking, drug use
- Occassional alcohol use during 1st trimester
- Family Hx: noncontributory

Maternal smoking

• BWI - nonsignificant OR

NBDPS - nonsignificant OR

Alcohol Use

- 77.6% ever use alcohol
- 58.8% drink while pregnant
- Conotruncal heart defects
 - California Birth Defect Monitoring Program
 - $\le 1X$ week OR = 1.3 (95% CI: 1.0, 1.9)
 - ≥ 1 week OR = 1.9 (95% CI: 1.0, 3.4)



Family History

Use of Family History Information in Pediatric Primary Care and Public Health

20.4 Recent Construction and Intelligence of Intelligence (Intelligence) and Construction (Intelligence) and Intelligence (

CDC-Sponsored Workgroup Meeting

February 24-25, 2006

Doubletree Hotel Atlanta-Buckhead 3342 Peachtree Rd, ME Atlanta, GA 30205

T I I I

- BWI
 - OR = 4.8
 - 95% CI: 2.1 10.8

Maternal prenatal labs

- HIV/RPR/Hep B negative
- Rubella immune

Congenital Rubella Syndrome



Rubella Immune

- Rubella vaccination introduced in US 1969
- 91% of US women seropositive for rubella
- 75% of Sri Lankan women positive for rubella IgG

Admission Note

 PE: General Appearance - term newborn, mild respiratory distress, minimal central cyanosis initially, no obvious congenital malformations

Down Syndrome

- Chromosome 21
- 50%
- Why??

Causes of Common Pediatric Conditions



Genetic Fact

Cystic FibrosisPKU

◆Birth Defects
◆Asthma
◆Prematurity

◆Trauma◆Child Abuse

Combined effect of homocysteine, smoking and MTHFR 677C>T genotype on CHD risk



HapMap Project



- International endeavor
 - Canada, China, Japan, Nigeria, United Kingdom and United States
 - Total of 270 individuals to be analyzed for 1 million SNPs
- Purpose
 - Provide a map of SNPs that will allow scientists to find and test susceptibility loci
 - Provide representative, genomewide haplotypes from different populations
 - Initial phase completed ahead of schedule
 - Publicly available data for 4 different populations

Birth Defects Research and Prevention





Why is Preconception Care a public health concern?



Preconception Care

- Risk assessment
- Health Promotion
- Intervention

Our Vision of Preconceptional Care

- Determine genetic susceptibilities: genome-wide association studies
- Establish genetic and metabolic high-risk profile



- Design targeted treatments
- The benefits will be widespread and many cannot even be predicted yet









Acknowledgements

Faculty

Staff

S. Jill James, Ph.D
Linda Jackson, RHIT, ARHMS
Stepan Melnyk, Ph.D.
Bettye Flowers, R.N.
Sadia Ghaffar, M.D.,
Weronica Smith, MBA
M.P.H.
Mario Cleves, Ph.D.
Bridget Mosley, MPH

Bridget Mosley, MPH

- Research efforts supported by:
 - Cooperative Agreement No. U50/CCU613236-06 from the Centers for Disease Control and Prevention (CDC) and
- Most importantly, infants and their parents who have willingly participated in both the NBDPS and NICHD-funded study.